Announces

Morria Biopharmaceuticals Plc. Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a …
LONDON & NEW YORK—-Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal…